葉氏化工集團(00408.HK)建議分拆洋紫荊浙江在A股獨立上市
格隆匯 7 月 21日丨葉氏化工集團(00408.HK)發佈公告,受限於若干條件,公司建議尋求洋紫荊浙江(於該公告日期為公司間接擁有91.76%的附屬公司,主要從事油墨業務)的A股於深圳證券交易所獨立上市。於該公告日期,公司已取得聯交所批准進行建議分拆。
假設根據建議A股上市將予發行的新A股數目將佔洋紫荊浙江經擴大已發行股本的25%,預期公司於洋紫荊浙江的擁有權將由於該公告日期約91.76%攤薄至建議A股上市後約68.82%。因此,倘建議分拆落實,其將構成上市規則第14.29條項下視作出售集團於洋紫荊浙江的權益。公司將召開及舉行股東特別大會以供獨立股東考慮並酌情批准建議分拆。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.